Shares of Aimmune Therapeutics (AIMT) are on the rise on Wednesday after the Food and Drug Administration posted briefing documents ahead of a panel meeting to review the company’s peanut allergy treatment Palforzia. Arguing that the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id2961761/-Aimmune-jumps-as-FDA-materials-seen-as-good-sign-for-peanut-allergy-treatment)